PROCEPT BioRobotics (PRCT) EVP sells 3,243 shares under 10b5-1 plan

Rhea-AI Filing Summary

PROCEPT BioRobotics EVP, CLO and Corporate Secretary Alaleh Nouri sold 3,243 shares of common stock in open-market transactions. The sales on March 10, 2026 occurred at weighted average prices of $25.6037 and $26.7379 per share under a Rule 10b5-1 trading plan adopted on June 4, 2025. Following these transactions, Nouri directly holds 111,021 shares of PROCEPT BioRobotics common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nouri Alaleh

(Last) (First) (Middle)

C/O PROCEPT BIOROBOTICS CORPORATION

150 BAYTECH DRIVE

(Street)

SAN JOSE CA 95134

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PROCEPT BioRobotics Corp [ PRCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, CLO, CORP. SEC.

3. Date of Earliest Transaction (Month/Day/Year)
03/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/10/2026		S(1)		3,098	D	$25.6037(2)	111,166	D
Common Stock	03/10/2026		S(1)		145	D	$26.7379(3)	111,021	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 4, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.11 to $25.96 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.365 to $26.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Remarks:

	/s/ Jonathan Stone, Attorney-in-Fact for Alaleh Nouri	03/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did PROCEPT BioRobotics (PRCT) report for Alaleh Nouri?

PROCEPT BioRobotics reported that executive Alaleh Nouri sold 3,243 common shares. The EVP, CLO and Corporate Secretary completed two open-market sales on March 10, 2026, as disclosed in a Form 4 insider trading report filed with regulators.

How many PROCEPT BioRobotics (PRCT) shares did Alaleh Nouri sell and at what prices?

Alaleh Nouri sold a total of 3,243 PROCEPT BioRobotics common shares. The weighted average sale prices were $25.6037 per share for 3,098 shares and $26.7379 per share for 145 shares, executed in multiple transactions within disclosed price ranges.

How many PROCEPT BioRobotics (PRCT) shares does Alaleh Nouri hold after the Form 4 sales?

After the reported sales, Alaleh Nouri directly holds 111,021 PROCEPT BioRobotics shares. This post-transaction ownership figure reflects her remaining direct position in the company’s common stock as of the March 10, 2026 transactions.

Were the PROCEPT BioRobotics (PRCT) insider sales by Alaleh Nouri under a Rule 10b5-1 plan?

Yes. The filing states the sales were made under a Rule 10b5-1 trading plan. This pre-arranged plan was adopted by Alaleh Nouri on June 4, 2025, and governs how and when her shares are sold.

What type of transactions did PROCEPT BioRobotics (PRCT) disclose in this Form 4?

The Form 4 discloses two open-market sales of common stock by Alaleh Nouri. Both are coded as “S” transactions, described as sales in open market or private transactions, and involve non-derivative common stock rather than options or other derivatives.

What price ranges applied to Alaleh Nouri’s PROCEPT BioRobotics (PRCT) share sales?

The reported prices are weighted averages across multiple trades within specified ranges. One sale block occurred between $25.11 and $25.96 per share, and the other between $26.365 and $26.98 per share, with full trade breakdowns available on request.